Telomeres and telomerase in cancer stem cells

European Journal of Cancer

Volumn 42, Issue 9, 2006, Pages 1197-1203

  Ju, Zhenyu ^a   Rudolph, Karl Lenhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Ageing; Apoptosis; Cell cycle arrest; Chromosomal instability; DNA damage; p21; p53; Senescence; Telomerase; Telomeres

Indexed keywords

TELOMERASE;

ARTICLE; BRAIN CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER STEM CELL; CELL DEATH; CHROMOSOMAL INSTABILITY; CHROMOSOME DISORDER; CHROMOSOME STRUCTURE; DNA DAMAGE; DYNAMICS; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TELOMERE; TUMOR GROWTH;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE; TUMOR STEM CELLS;

EID: 33744535197     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.040     Document Type: Article

References (76)

1. Blackburn E.H. Structure and function of telomeres. Nature 350 (1991) 569-573
2. Blasco M.A., Lee H.W., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
3. Blackburn E.H. Switching and signaling at the telomere. Cell 106 (2001) 661-673
4. de Lange T. Protection of mammalian telomeres. Oncogene 21 (2002) 532-540
5. Hackett J.A., Feldser D.M., and Greider C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell 106 (2001) 275-286
6. Allsopp R.C., Chang E., Kashefi-Aazam M., et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 220 (1995) 194-200
7. Levy M.Z., Allsopp R.C., Futcher A.B., Greider C.W., and Harley C.B. Telomere end-replication problem and cell aging. J Mol Biol 225 (1992) 951-960
8. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 89 (1992) 10114-10118
9. Allsopp R.C., and Harley C.B. Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res 219 (1995) 130-136
10. Djojosubroto M.W., Choi Y.S., Lee H.W., and Rudolph K.L. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 15 (2003) 164-175
11. Lee H.W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W., and DePinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 392 (1998) 569-574
12. Wright W.E., and Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27 (1992) 383-389
13. Counter C.M., Avilion A.A., LeFeuvre C.E., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11 (1992) 1921-1929
14. Nakamura T.M., Morin G.B., Chapman K.B., et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277 (1997) 955-959
15. Meyerson M., Counter C.M., Eaton E.N., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
16. Blasco M.A., Rizen M., Greider C.W., and Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 12 (1996) 200-204
17. Satyanarayana A., Manns M.P., and Rudolph K.L. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40 (2004) 276-283
18. Plentz R.R., Caselitz M., Bleck J.S., et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40 (2004) 80-86
19. Plentz R.R., Wiemann S.U., Flemming P., et al. Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer. Gut 52 (2003) 1304-1307
20. Rudolph K.L., Millard M., Bosenberg M.W., and DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28 (2001) 155-159
21. Rudolph K.L., Chang S., Lee H.W., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96 (1999) 701-712
22. Greenberg R.A., Chin L., Femino A., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97 (1999) 515-525
23. Gonzalez-Suarez E., Samper E., Flores J.M., and Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 26 (2000) 114-117
24. Artandi S.E., Chang S., Lee S.L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
25. d'Adda D.F., Reaper P.M., Clay-Farrace L., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198
26. Kirk K.E., Harmon B.P., Reichardt I.K., Sedat J.W., and Blackburn E.H. Block in anaphase chromosome separation caused by a telomerase template mutation. Science 275 (1997) 1478-1481
27. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
28. O'Sullivan J.N., Bronner M.P., Brentnall T.A., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32 (2002) 280-284
29. Plentz R.R., Schlegelberger B., Flemming P., et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology 42 3 (2005) 522-526
30. Takai H., Smogorzewska A., and de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 13 (2003) 1549-1556
31. Satyanarayana A., Greenberg R.A., Schaetzlein S., et al. Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol 24 (2004) 5459-5474
32. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
33. Chin L., Artandi S.E., Shen Q., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97 (1999) 527-538
34. Chin K., de Solorzano C.O., Knowles D., et al. In situ analyses of genome instability in breast cancer. Nat Genet 36 (2004) 984-988
35. Lechel A., Satyanarayana A., Ju Z., et al. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep 6 (2005) 275-281
36. Counter C.M., Botelho F.M., Wang P., Harley C.B., and Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J Virol 68 (1994) 3410-3414
37. Stewart S.A. Telomere maintenance and tumorigenesis: an 'ALT'ernative road. Curr Mol Med 5 (2005) 253-257
38. Gonzalez-Suarez E., Samper E., Ramirez A., et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 20 (2001) 2619-2630
39. Artandi S.E., Alson S., Tietze M.K., et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 99 (2002) 8191-8196
40. Li S., Rosenberg J.E., Donjacour A.A., et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 64 (2004) 4833-4840
41. Smith L.L., Coller H.A., and Roberts J.M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5 (2003) 474-479
42. Li S., Crothers J., Haqq C.M., and Blackburn E.H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 280 25 (2005) 23709-23717
43. Clark G.M., Osborne C.K., Levitt D., Wu F., and Kim N.W. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 89 (1997) 1874-1881
44. Albanell J., Lonardo F., Rusch V., et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 89 (1997) 1609-1615
45. Harley C.B. Telomerase therapeutics for degenerative diseases. Curr Mol Med 5 (2005) 205-211
46. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
47. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
48. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., and Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17 (2003) 3029-3035
49. So C.W., Karsunky H., Wong P., Weissman I.L., and Cleary M.L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103 (2004) 3192-3199
50. Passegue E., Jamieson C.H., Ailles L.E., and Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci USA 100 Suppl. 1 (2003) 11842-11849
51. Al Hajj M., and Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 23 (2004) 7274-7282
52. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003) 5821-5828
53. Zimmermann S., and Martens U.M. Telomere dynamics in hematopoietic stem cells. Curr Mol Med 5 (2005) 179-185
54. Zimmermann S., Glaser S., Ketteler R., Waller C.F., Klingmuller U., and Martens U.M. Effects of telomerase modulation in human hematopoietic progenitor cells. Stem Cells 22 (2004) 741-749
55. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., and Moore M.A. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 90 (1997) 182-193
56. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., and Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 91 (1994) 9857-9860
57. Vulliamy T., Marrone A., Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413 (2001) 432-435
58. Mason P.J., Wilson D.B., and Bessler M. Dyskeratosis congenita - a disease of dysfunctional telomere maintenance. Curr Mol Med 5 (2005) 159-170
59. Herrera E., Samper E., Martin-Caballero J., Flores J.M., Lee H.W., and Blasco M.A. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 18 (1999) 2950-2960
60. Satyanarayana A., Wiemann S.U., Buer J., et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 22 (2003) 4003-4013
61. Aladjem M.I., Spike B.T., Rodewald L., et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8 (1998) 145-155
62. Hong Y., and Stambrook P.J. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci USA 101 (2004) 14443-14448
63. Ohyashiki J.H., Sashida G., Tauchi T., and Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 21 (2002) 680-687
64. Ju Z, Rudolph KL. Telomeres and telomerase in stem cells during aging and disease. Genome dynamics, vol. 1: genome and disease; 2005.
65. Greenberg P., Cox C., LeBeau M.M., Fenaux P., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
66. Ladetto M., Compagno M., Ricca I., et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 103 (2004) 4644-4649
67. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., and Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 11 (1997) 190-194
68. Brummendorf T.H., Rufer N., Holyoake T.L., et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann NY Acad Sci 938 (2001) 293-303
69. Brummendorf T.H., Holyoake T.L., Rufer N., et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95 (2000) 1883-1890
70. Ohyashiki J.H., Iwama H., Yahata N., et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 5 (1999) 1155-1160
71. Sieglova Z., Zilovcova S., Cermak J., et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. Leuk Res 28 (2004) 1013-1021
72. Mason P.J., Wilson D.B., and Bessler M. Dyskeratosis congenita - a disease of dysfunctional telomere maintenance. Curr Mol Med 5 (2005) 159-170
73. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., and Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 60 (2000) 610-617
74. Ohyashiki K., Iwama H., Yahata N., et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 42 (2001) 291-299
75. Kiel M.J., Yilmaz O.H., Iwashita T., Yilmaz O.H., Terhorst C., and Morrison S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121 (2005) 1109-1121
76. Zimmermann S., Voss M., Kaiser S., Kapp U., Waller C.F., and Martens U.M. Lack of telomerase activity in human mesenchymal stem cells. Leukemia 17 (2003) 1146-1149